7 results
In this study, we want to find out whether the new drug capmatinib is more effective (i.e. better inhibits the growth of cancer cells) than the widely used chemotherapy docetaxel. In addition, it will be assessed whether treatment with capmatinib is…
Efficacy of BEZ235 on objective response rate according to RECIST 1.1
The study will look at patients with Squamous Cell Head and Neck Cancer (SCCHN) whose tumours express a certain type of protein called PD-L1. The research aims to compare a new drug called nivolumab against Investigator's choice of chemotherapy…
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
The primary objective of this study is to compare the overall survival (OS) of ramucirumab DP administered in combination with docetaxel versus docetaxel with placebo as therapy for patients with Stage IV non-small cell lung cancer (NSCLC) who have…
To assess the treatment effect of BEZ235 relative to everolimus on progression free survival in patients with advanced pancreatic neuroendocrine tumors who have not been previously treated with an mTOR inhibitor.
The primary objective of this trial is to investigate the proposed beneficial effect of raloxifene as compared to placebo when given for twelve weeks in addition to antipsychotic medication to patients with a psychotic disorder. We expect lower…